Endocrine diseases

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on: 
Monday, August 2, 2021

BOSTON and JERUSALEM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its poster presentation titled “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis” has been selected by the Program Committee of the American Society for Bone and Mineral Research (ASBMR) for its Annual Meeting scheduled to take place on October 1-4, 2021 in San Diego, California. Dr. Arthur Santora, Entera’s Chief Medical Officer, will present the poster at both the plenary session on October 1 and the general session on October 2, as well as a special session on the Biology of the Aging Skeleton Symposium on September 30.

Key Points: 
  • Three and 6 month results, previously reported by Entera in June 2021 can be found here .
  • Osteoporosis, characterized by low bone mass and deterioration of bone tissue, can lead to decreased bone strength and increased risk of fracture.
  • The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on: 
Thursday, July 29, 2021

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points: 
  • This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
  • The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
  • This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
  • Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

IM Therapeutics Co-Founder and CMO Peter Gottlieb, M.D, to Present Advances in Genetically Targeted Therapies for Type 1 Diabetes at the 2021 ADA Scientific Sessions

Retrieved on: 
Thursday, June 24, 2021

IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81st Scientific Sessions, held June 25-29, 2021.

Key Points: 
  • IM Therapeutics, Inc. announced today that Peter Gottlieb, M.D., Co-founder and Chief Medical Officer, will present at the American Diabetes Association (ADA) 81st Scientific Sessions, held June 25-29, 2021.
  • IM Therapeutics is a clinical-stage company developing novel, first-in-class therapies targeting human leukocyte antigens (HLAs) to treat autoimmune diseases.
  • Dr. Gottliebs talk, entitled Genetically Selected Patients for Targeted Immune Therapy, will take place during the Personalized Medicine for Immune Therapies in Type 1 Diabetes session on Sunday, June 27.
  • The Company is building a broad HLA-targeted pipeline in autoimmune disorders including type 1 diabetes, celiac disease, and lupus.

Thyroid Cancer Pipeline Insight Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 24, 2021

The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Thyroid cancer - Pipeline Insight, 2021" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape.
  • This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association

Retrieved on: 
Wednesday, June 23, 2021

The ADA is the US leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.

Key Points: 
  • The ADA is the US leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.
  • It holds annual scientific sessions to bring together the latest, cutting-edge advances in diabetes research, prevention and care.
  • NASH is a liver disease characterized by an accumulation of fat (lipid droplets), along with inflammation and degeneration of hepatocytes.
  • GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases.

A Prospective Study in More Than 1,000 Osteoporosis Patients Concluded That Binosto® (Buffered Soluble Alendronate) May Increase Patient Satisfaction, Long-Term Adherence and Therefore Efficacy

Retrieved on: 
Tuesday, June 22, 2021

The study enrolled 1,084 postmenopausal women with osteoporosis, newly prescribed Binosto and nave to bisphosphonate therapy.

Key Points: 
  • The study enrolled 1,084 postmenopausal women with osteoporosis, newly prescribed Binosto and nave to bisphosphonate therapy.
  • At baseline, 31% of enrolled patients reported a medical history of gastrointestinal (GI) tract conditions that did not exclude study participation.
  • The cumulative incidence of all upper GI AEs related to Binosto observed during the duration of the study was low at 9.6%.
  • Binosto (Buffered Soluble Alendronate) is a first-line treatment of postmenopausal osteoporosis patients that is associated with preferable pharmacologic properties translating into clinical benefit for patients.

Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism

Retrieved on: 
Monday, June 21, 2021

SPR001-201 and SPR001-202 comprised the entire Phase 2a clinical development program for tildacerfont in adult classic CAH.

Key Points: 
  • SPR001-201 and SPR001-202 comprised the entire Phase 2a clinical development program for tildacerfont in adult classic CAH.
  • Tildacerfont has been evaluated in 171 patients across seven clinical trials in which it has been generally well tolerated.
  • Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess.
  • Such forward-looking statements include statements regarding, among other things, the results, conduct, progress and timing of Spruces clinical trials.

Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials

Retrieved on: 
Friday, June 4, 2021

Expanding safe and clinically effective treatment options for obesity management is good news for people with obesity and the medical community."

Key Points: 
  • Expanding safe and clinically effective treatment options for obesity management is good news for people with obesity and the medical community."
  • It is not known if Wegovy is safe and effective when taken with other prescription, over-the- counter, or herbal weight loss products.
  • In studies with rodents, Wegovy and medicines that work like Wegovy caused thyroid tumors, including thyroid cancer.
  • Do not use Wegovy if:
    you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy.

Radius Health Business Update

Retrieved on: 
Wednesday, June 2, 2021

TYMLOS new patient adds in April: modest growth vs. previous 4-month trailing averages

Key Points: 
  • TYMLOS new patient adds in April: modest growth vs. previous 4-month trailing averages
    Meaningful FDA guidance on generic peptide requirements published on May 19, 2021
    Anticipate abaloparatide depot formulation technical development work to commence 2H, 2021
    BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (NASDAQ: RDUS), provided a business update covering continued progress for the Company.
  • Additional business updates will be provided as progress is achieved.
  • Radius views this new guidance as meaningful in assessing the probability of a generic synthetic peptide being filed and gaining market entry.
  • Radius lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

DayTwo, a Leader in Precision Medicine With the World’s Largest Microbiome Discovery Platform, Announces New Behavioral Science Approach for Diabetes Care

Retrieved on: 
Thursday, May 27, 2021

The model was developed by DayTwos clinical team including staff psychologists, behavioral scientists and gastroenterologists with expertise in the gut/brain axis.

Key Points: 
  • The model was developed by DayTwos clinical team including staff psychologists, behavioral scientists and gastroenterologists with expertise in the gut/brain axis.
  • Diabetes can lead to depression and depression can lead to diabetes.
  • With EATS, DayTwo has yet again reinvented the metabolic disease care model by incorporating a unique approach that addresses mental health.
  • DayTwo, a leader in precision medicine with the worlds largest and highest resolution microbiome discovery platform, offers a sustainable path to remission for metabolic disease (diabetes, prediabetes, clinical obesity, non-alcoholic fatty liver disease).